Search Medical Condition
Please enter condition
Please choose location from dropdown

Huntersville, North Carolina Clinical Trials

A listing of Huntersville, North Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (72) clinical trials

A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

Subjects will be transitioned to JZP-258 based on their treatment status at study entry. All subjects will begin JZP-258 treatment at the beginning of this period and continue through Week 12. They will be treated with JZP-258 alone for the final two weeks of this 12-week period. Once the JZP-258 ...

Phase

0.0 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This is an open-label, multi-center, Phase 1 dose-escalation and dose expansion study to define a MTD, describe preliminary safety, and to assess PK, immunogenicity, and potential anti-tumor activity of INCMGA00012 administered on either every two week or every four week schedules in patients with relapsed/ refractory or unresectable locally/ advanced ...

Phase

0.0 miles

Learn More »

This is an open label, non-randomized, multi-center study. The primary purpose of the study is to evaluate the safety, tolerability and efficacy of Epacadostat and Durvalumab when given in combination in patients with Selected Advanced Solid Tumors.

Phase N/A

0.0 miles

Learn More »

This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 2 parts (Part 1a and Part 1b). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (INCB039110) in combination with an IDO1 inhibitor (epacadostat; INCB024360; Group A) ...

Phase N/A

0.0 miles

Learn More »

Analysis of Orthodontic Tooth Movement Using 3D Imaging

Many archwire dimensions and two main bracket types (twin and self-ligating) are available to orthodontists for the first stage of orthodontic treatment, but little objective clinical evidence is available to indicate which archwire dimension and bracket type is ideal for a given patient with an individual type and degree of ...

Phase N/A

0.0 miles

Learn More »

CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers

This is a phase 1/1b open label, multicenter, dose-selection study of CPI-006, a Type 2 humanized IgG1 antibody inhibiting enzymatic activity of CD73 and adenosine production. This trial will study the safety, tolerability, and anti-tumor activity of CPI-006 as a single agent, in combination with CPI-444, a small molecule targeting ...

Phase

0.0 miles

Learn More »

A Study of ABBV-927 and ABBV-181 an Immunotherapy in Subjects With Advanced Solid Tumors

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Phase

1.64 miles

Learn More »

A Study of ABBV-181 in Participants With Advanced Solid Tumors

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine. The study will consist ...

Phase

1.64 miles

Learn More »

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

This is a multicenter, open-label, Phase 1 study of SC-006 given s a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and Part C ...

Phase

1.64 miles

Learn More »

A Study of the Safety Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific ...

Phase

1.64 miles

Learn More »